News
Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...
In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?
Actio Biosciences has closed a Series B financing round, raising $66m for advancing the genetics-driven small molecule ...
This was the stock's second consecutive day of losses.
Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...
Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as expected in the third quarter of this year.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback